ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows a decrease in net loss, but reliance on recent financing raises sustainability concerns. Product updates are promising, with trial expansions and positive biomarker feedback, yet delays in data release and manufacturing challenges persist. The Q&A reveals enthusiasm but also uncertainties in trial outcomes and biomarker validation. The absence of a market cap limits prediction precision, but the overall cautious outlook and mixed signals suggest a neutral stock price movement in the short term.
Key Financial Performance
Cash, cash equivalents, and investments $48.3 million at the end of Q4 2025, before the equity financing in February 2026.
Net proceeds from equity financing $140.4 million after deducting underwriting discount and other offering expenses.
GAAP net loss for Q4 2025 $22.8 million, or $0.42 per basic and diluted share, compared to $29.2 million, or $0.55 per share, in Q4 2024. The decrease is attributed to lower stock compensation, personnel costs, and preclinical costs following pipeline prioritization.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Evorpacept (Evo): Demonstrated potential across various combinations and tumor types. Validated CD47 as a biomarker for HER2-positive gastric and breast cancer. Phase II ASPEN-09 breast trial ongoing with top-line data expected in mid-2027. Potential to address CD47 expression in a large patient population.
ALX2004: Progressing in Phase I trial with dose escalation ongoing. Designed as a novel EGFR-targeted ADC with promising preclinical data. Safety data from dose escalation expected in the second half of 2026.
Market Expansion for Evorpacept: Focus on HER2-positive gastric and breast cancer patients with CD47 overexpression. Potential to expand into other tumor types and hematologic malignancies.
Market Expansion for ALX2004: Targeting EGFR-expressing solid tumors such as non-small cell lung cancer, colorectal cancer, and head and neck cancer.
Clinical Development Progress: Evorpacept and ALX2004 clinical programs remain on track. Site activations for Phase II ASPEN-09 breast trial progressing globally.
Financial Position: Completed $150 million financing, extending cash runway through the first half of 2028. Focused on executing key clinical trials.
Strategic Focus: Prioritizing evorpacept and ALX2004 clinical programs. Developing a companion diagnostic for CD47 expression to enable targeted patient selection.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Clinical trial timelines: Potential delays in clinical trial timelines for evorpacept and ALX2004, which could impact the company's ability to meet its goal of pivotal study readiness by the end of next year.
Regulatory approval: Uncertainty around regulatory approval processes for evorpacept and ALX2004, especially given the need for companion diagnostics and biomarker-driven approaches.
Market competition: Competitive pressures in the oncology market, particularly in HER2-positive breast cancer and EGFR-expressing solid tumors, which could limit market share.
Financial sustainability: Dependence on recent $150 million financing to sustain operations through 2028, with risks if additional funding is required earlier than anticipated.
Treatment landscape changes: Shifts in the treatment landscape for HER2-positive breast cancer, particularly post-ENHERTU, which could affect the positioning and adoption of evorpacept.
Supply chain and manufacturing: Potential challenges in scaling up manufacturing for evorpacept and ALX2004 as they progress to later-stage trials and commercialization.
Biomarker validation: Reliance on CD47 as a predictive biomarker, which may not be universally validated or accepted, potentially limiting patient selection and treatment efficacy.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Evorpacept (Evo) Development: The company plans to advance evorpacept to pivotal studies by the end of 2026. Top-line data for 80 patients from the ongoing Phase II ASPEN-09 breast cancer trial is expected in mid-2027. The trial will evaluate patient responses by CD47 level to define the predictive potential of this biomarker. The company is also pursuing a targeted oncology approach for additional tumor types and is developing a companion diagnostic for CD47 expression.
ALX2004 Development: The company aims to advance ALX2004, an EGFR-targeted ADC, to a registration study. Full safety data from the dose escalation cohort is expected in the second half of 2026. The program is currently in Phase I, with dose escalation ongoing.
Financial Guidance: The company has sufficient cash and investments to fund operations through the first half of 2028. Key milestones include biomarker analysis readout for evorpacept in May 2026, ALX2004 safety data in the second half of 2026, and evorpacept top-line data in mid-2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you confirm if the interim look at ASPEN-Breast is off the table in favor of the 80-patient readout next year?
A:Yes, the interim look is off the table. The company is guiding towards 80 patients with full data expected in mid-next year. The goal is to communicate robust data and ensure enough CD47 positive patients are included.
Q:What is the rationale behind upsizing to 120 patients and changing the primary endpoint?
A:The upsizing ensures robust numbers of patients in various subpopulations, particularly those with CD47 overexpression. The primary endpoint was changed to focus on CD47 as it is seen as the most powerful predictor of response. This change aims to provide data that drives the proposed cut point for regulatory purposes.
Q:What feedback are you getting from investigators on the biomarker approach and enrollment trends in ASPEN-Breast?
A:Investigators are excited about the biomarker approach as it allows for identifying a population that will benefit significantly from the therapy. Enrollment trends are early but promising, with site activation going well and enthusiasm from investigators.
Q:Why has the safety data for ALX2004 been moderately pushed out?
A:The change is to ensure robust and meaningful data communication. By the end of the year, fulsome data from the dose escalation phase is expected, which will allow for clearer communication about expected doses.
Q:Is it safe to expect up to 4 dose levels to have been tested by the time of disclosure for ALX2004?
A:Yes, it is reasonable to expect up to 4 dose levels to have been tested. The study has progressed well, with no dose-limiting toxicities observed so far.
Q:What is the expected ratio of CD47 high versus low expression in the 80 patients in ASPEN-09?
A:Approximately half of the population is expected to be CD47 high, based on literature and previous studies. This percentage is consistent across different tumor types.
Q:Why is the therapeutic dose range for ALX2004 different from other EGFR ADCs using TOP1?
A:The difference may be due to a wider therapeutic window for ALX2004, which could lead to better efficacy. The highest non-severely toxic dose in primates was 20, equivalent to around 6.5 mg/kg in patients, and the study is progressing with smaller incremental increases in dose.
Q:What is the logic behind expanding the ASPEN-09 trial to 120 patients?
A:The expansion is to ensure a robust Phase II study and to de-risk the Phase III trial. There has been no change in assumptions regarding percentages or efficacy.
Q:How are interstitial lung disease (ILD) and skin toxicity being monitored in ALX2004?
A:ILD is monitored through regular CT scans, and skin toxicity is assessed during clinic visits. The non-human primate studies showed no evidence of ILD, and the selected antibody for ALX2004 has shown lower skin toxicity in early studies.
Q:Is the IHC cutoff for ASPEN-09 primary endpoint already locked in?
A:No, the cutoff is not locked in. The study aims to determine the optimal cutoff, which may vary across tumor types. Tissue from the time of diagnosis is used to assess CD47 expression, and missing data is expected to be minimal.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact timing of data releases for ALX2004 and ASPEN-09, as well as the precise IHC cutoff for CD47 expression. They also used vague language regarding the potential variability in chemotherapy options and their impact on CD47 expression.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALX progress
Breast Conference
CR rate
ESMO Breast
Number
Phase trial
Slide deck
Slides deck
activation
analysis trial
antibody bispecifics
anticancer antibody
balance sheet
biomarker analysis
cancer update
combination zanidatamab
confidence
dose level
end
endpoint
financing
investment
line patient
loss month
lymphoma patient
mg kilo
mid
month share
offering cash
opportunity readout
potential evorpacept
program ALX
program month
progress program
role
spend
subset
ALXO Transcript
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
Unknown5-9
The earnings call presented a mixed outlook. Financial metrics were not fully disclosed, and management's responses in the Q&A lacked clarity, raising uncertainties. However, the company’s strategic initiatives, including advancing key drug candidates and a solid financial runway, provide a stable foundation. No strong catalysts or detractors were evident, suggesting a neutral stock price movement over the next two weeks.
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call presents a mixed picture. Financial performance shows a decrease in net loss, but reliance on recent financing raises sustainability concerns. Product updates are promising, with trial expansions and positive biomarker feedback, yet delays in data release and manufacturing challenges persist. The Q&A reveals enthusiasm but also uncertainties in trial outcomes and biomarker validation. The absence of a market cap limits prediction precision, but the overall cautious outlook and mixed signals suggest a neutral stock price movement in the short term.
ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript
Positive11-7
The company's strategic focus on biomarker-driven approaches and strong clinical trial results in HER2-positive cancers indicate promising developments. The extension of the cash runway into 2027 and the Sanofi collaboration further enhance the outlook. Despite some uncertainties in execution and supply chain risks, the positive clinical data and strategic partnerships suggest a positive market reaction.
ALXO Slides
ALXO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
